Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial

Yehuda Carmeli(Tel Aviv University), Surbhi Malhotra‐Kumar(University of Antwerp), Herman Goossens(University of Antwerp), Joseph W. Chow(Pfizer (United States)), Illia Gumenchuk(Kyiv City Clinical Oncology Center), Rienk Pypstra(Pfizer (United States)), Minggui Wang(Fudan University), Francis F. Arhin(Pfizer (United States)), George L. Daikos(National and Kapodistrian University of Athens), Julián Torre‐Cisneros(Instituto de Salud Carlos III), Joanne L. Leaney(Pfizer (United Kingdom)), O. V. Pyptіuk(Ivano-Frankivsk National Medical University), Jesús Rodríguez‐Baño(Hospital Universitario Virgen Macarena), Firdevs Aksoy(Karadeniz Technical University), Mical Paul(Technion – Israel Institute of Technology), Michele Wible, Gang Chen(Tongji Hospital), Yongjie Zhao(Union General Hospital), Lu Liang(Fudan University), Halley Rogers(Pfizer (United States)), Ivan Titov(Ivano-Frankivsk National Medical University), Alison Luckey(Global Antibiotic Research & Development Partnership), Christine Lammens, R. Jiménez-Rodríguez(Hospital Universitario Virgen del Rocío), George Singer(UCLA Medical Center), Marc Bonten, José Miguel Cisneros(Instituto de Salud Carlos III)
The Lancet Infectious Diseases
October 7, 2024
Cited by 98


Related Papers